rs139522696
Variant summary
Our verdict is Uncertain significance. Variant got 0 ACMG points: 2P and 2B. PM2BP4_Moderate
The ENST00000256190.13(SBF2):āc.3831C>Gā(p.Ile1277Met) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00029 in 1,614,034 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
ENST00000256190.13 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 0 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SBF2 | NM_030962.4 | c.3831C>G | p.Ile1277Met | missense_variant | 29/40 | ENST00000256190.13 | NP_112224.1 | |
SBF2 | NM_001386339.1 | c.3927C>G | p.Ile1309Met | missense_variant | 30/41 | NP_001373268.1 | ||
SBF2 | NM_001386342.1 | c.3702C>G | p.Ile1234Met | missense_variant | 28/39 | NP_001373271.1 | ||
SBF2 | XM_047427657.1 | c.3927C>G | p.Ile1309Met | missense_variant | 30/35 | XP_047283613.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SBF2 | ENST00000256190.13 | c.3831C>G | p.Ile1277Met | missense_variant | 29/40 | 1 | NM_030962.4 | ENSP00000256190 | P3 |
Frequencies
GnomAD3 genomes AF: 0.000204 AC: 31AN: 152174Hom.: 0 Cov.: 31
GnomAD3 exomes AF: 0.000215 AC: 54AN: 251302Hom.: 0 AF XY: 0.000199 AC XY: 27AN XY: 135836
GnomAD4 exome AF: 0.000299 AC: 437AN: 1461860Hom.: 0 Cov.: 31 AF XY: 0.000286 AC XY: 208AN XY: 727230
GnomAD4 genome AF: 0.000204 AC: 31AN: 152174Hom.: 0 Cov.: 31 AF XY: 0.000175 AC XY: 13AN XY: 74350
ClinVar
Submissions by phenotype
not provided Uncertain:3Benign:1
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Dec 02, 2024 | Observed in patient with peripheral neuropathy in published literature; however, a second variant was not identified (PMID: 25025039); In silico analysis indicates that this missense variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 24290377, 25025039) - |
Uncertain significance, criteria provided, single submitter | clinical testing | Athena Diagnostics | Mar 30, 2022 | - - |
Uncertain significance, criteria provided, single submitter | not provided | Breakthrough Genomics, Breakthrough Genomics | - | - - |
Likely benign, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Mar 01, 2024 | SBF2: BP4 - |
Charcot-Marie-Tooth disease type 4B2 Uncertain:3
Uncertain significance, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Jul 25, 2019 | The SBF2 c.3831C>G; p.Ile1277Met variant (rs139522696), has been reported in the heterozygous state in individuals affected with CMT and in a control individual (Hoyer 2014). However, the p.Ile1277Met variant was not predicted to be associated with CMT. This variant is found in the general population with an overall allele frequency of 0.02 % (60/ 282,692 alleles) in the Genome Aggregation Database. The isoleucine at codon 1277 is moderately conserved, and computational analyses (SIFT, PolyPhen-2) predict that this variant is tolerated. However, given the lack of clinical and functional data, the significance of the p.Ile1277Met variant is uncertain at this time. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Apr 11, 2022 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jan 13, 2018 | This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score, this variant could not be ruled out of causing disease and therefore its association with disease required further investigation. A literature search was performed for the gene, cDNA change, and amino acid change (if applicable). No publications were found based on this search. This variant was therefore classified as a variant of unknown significance for this disease. - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Genetic Services Laboratory, University of Chicago | May 06, 2016 | - - |
Inborn genetic diseases Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Dec 06, 2019 | The p.I1277M variant (also known as c.3831C>G), located in coding exon 29 of the SBF2 gene, results from a C to G substitution at nucleotide position 3831. The isoleucine at codon 1277 is replaced by methionine, an amino acid with highly similar properties. This alteration was detected in the heterozygous state in one reported patient with Charcot-Marie-Tooth disease; however, a second SBF2 alteration was not identified in this patient, and the alteration was also present in one control (Høyer H et al. Biomed Res Int, 2014 Jun;2014:210401). This amino acid position is highly conserved through mammals but not in all available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
Charcot-Marie-Tooth disease type 4 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Oct 13, 2022 | This sequence change replaces isoleucine, which is neutral and non-polar, with methionine, which is neutral and non-polar, at codon 1277 of the SBF2 protein (p.Ile1277Met). This variant is present in population databases (rs139522696, gnomAD 0.05%). This variant has not been reported in the literature in individuals affected with SBF2-related conditions. ClinVar contains an entry for this variant (Variation ID: 246374). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt SBF2 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at